Mirikizumab, sold under the brand name Omvoh, is a monoclonal antibody used for the treatment of ulcerative colitis. It is designed to attach to interleukin-23 (IL-23) and block its activity.

The most common side effects include upper respiratory tract infections (nose and throat infections), headache, rash and reactions at the site of injection (when given by injection under the skin).

Mirikizumab was approved for medical use in the European Union in May 2023, and in the United States in October 2023.

In the European Union, mirikizumab is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

In the United States, mirikizumab is indicated for the treatment of adults with moderately to severely active ulcerative colitis. In January 2025, the US Food and Drug Administration (FDA) expanded the indication for mirikizumab to include the treatment of moderately to severely active Crohn's disease in adults.

Mirikizumab was developed by Eli Lilly and Company.

The approval was based on the LUCENT 1 clinical study which evaluated the safety and efficacy of mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

All participants enrolled in the program had a diagnosis of UC for at least three months prior to baseline and a confirmed diagnosis of moderately or severely active UC, as assessed by the modified Mayo score (MMS).